Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group
Top Cited Papers
- 1 April 2017
- journal article
- review article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 18 (4), e206-e217
- https://doi.org/10.1016/s1470-2045(17)30189-4
Abstract
No abstract availableKeywords
This publication has 70 references indexed in Scilit:
- Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3Blood, 2013
- Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling dataHaematologica, 2012
- Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agentsHaematologica, 2012
- Place of modern imaging modalities for solitary plasmacytoma: Toward improved primary staging and treatment monitoringCritical Reviews in Oncology/Hematology, 2012
- 18F‐fluoro‐deoxyglucose positron emission tomography in assessment of myeloma‐related bone disease: A systematic reviewCancer, 2011
- Combining FDG-PET/CT with laboratory data yields superior results for prediction of relapse in multiple myeloma*European Journal of Haematology, 2011
- F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myelomaBlood, 2009
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid TumorsJournal of Nuclear Medicine, 2009
- 11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myelomaWorld Journal of Surgical Oncology, 2007
- Myeloma bone disease: pathophysiology and managementAnnals of Oncology, 2005